EBV-TCR-T cells
Phase 1Cell therapy
EBV-TCR-T cells is one of 10 biologic programs targeting Histiocytosis. It is currently in Phase 1.
2
Indications
4
Total Trials
2
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Histiocytosis
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Vepesid
AAvyxa
Approved
Decadron
AAspen Global Incorporated
Approved
Alkeran
AApotex Inc.
Approved
Leustatin
EMD SeronoApproved
Mekinist
NovartisPhase 2
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 2
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
EBV-TCR-T cells
FFujian Cancer Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Histiocytosis1 trial
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
Recruiting·—·Phase 1·NCT06135922·9 enrolled
Recurrent or Metastatic NPC1 trial
EBV Infection After Allogenic HSCT1 trial
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Recruiting·—·Phase 1·NCT06119256·12 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EBV-TCR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- FFujian Cancer Hospital